S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:OPRX

OptimizeRx Competitors

$39.54
-0.45 (-1.13 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.74
Now: $39.54
$40.51
50-Day Range
$25.15
MA: $31.27
$39.99
52-Week Range
$6.50
Now: $39.54
$40.51
Volume108,514 shs
Average Volume174,811 shs
Market Capitalization$597.41 million
P/E RatioN/A
Dividend YieldN/A
Beta0.56

Competitors

OptimizeRx (NASDAQ:OPRX) Vs. EVOP, TTGT, EGOV, CATM, RPAY, and CBZ

Should you be buying OPRX stock or one of its competitors? Companies in the industry of "business services, not elsewhere classified" are considered alternatives and competitors to OptimizeRx, including EVO Payments (EVOP), TechTarget (TTGT), NIC (EGOV), Cardtronics (CATM), Repay (RPAY), and CBIZ (CBZ).

OptimizeRx (NASDAQ:OPRX) and EVO Payments (NASDAQ:EVOP) are both computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, EVO Payments has a beta of 1.73, indicating that its stock price is 73% more volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 52.7% of EVO Payments shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 51.0% of EVO Payments shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and EVO Payments, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
EVO Payments05302.38

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. EVO Payments has a consensus target price of $24.00, indicating a potential downside of 12.70%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than EVO Payments.

Profitability

This table compares OptimizeRx and EVO Payments' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
EVO Payments-1.37%-6.43%2.97%

Valuation & Earnings

This table compares OptimizeRx and EVO Payments' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
EVO Payments$485.78 million4.68$-10,100,000.00$0.6641.65

OptimizeRx has higher earnings, but lower revenue than EVO Payments. OptimizeRx is trading at a lower price-to-earnings ratio than EVO Payments, indicating that it is currently the more affordable of the two stocks.

Summary

EVO Payments beats OptimizeRx on 7 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and TechTarget (NASDAQ:TTGT) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, TechTarget has a beta of 0.92, indicating that its stock price is 8% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 89.6% of TechTarget shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 16.4% of TechTarget shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and TechTarget, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
TechTarget00303.00

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. TechTarget has a consensus target price of $42.6667, indicating a potential downside of 37.75%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than TechTarget.

Profitability

This table compares OptimizeRx and TechTarget's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
TechTarget11.90%9.86%6.79%

Valuation & Earnings

This table compares OptimizeRx and TechTarget's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
TechTarget$133.96 million14.38$16.88 million$0.62110.55

TechTarget has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than TechTarget, indicating that it is currently the more affordable of the two stocks.

Summary

TechTarget beats OptimizeRx on 10 of the 12 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and NIC (NASDAQ:EGOV) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, NIC has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 89.7% of NIC shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 2.7% of NIC shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and NIC, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
NIC01313.00

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. NIC has a consensus target price of $27.75, indicating a potential upside of 1.09%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than NIC.

Profitability

This table compares OptimizeRx and NIC's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
NIC14.94%23.51%15.34%

Valuation & Earnings

This table compares OptimizeRx and NIC's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
NIC$354.20 million5.19$50.43 million$0.7735.65

NIC has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than NIC, indicating that it is currently the more affordable of the two stocks.

Summary

NIC beats OptimizeRx on 9 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and Cardtronics (NASDAQ:CATM) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Cardtronics has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 19.8% of Cardtronics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and Cardtronics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
Cardtronics13302.29

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Cardtronics has a consensus target price of $41.40, indicating a potential upside of 1.69%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Cardtronics.

Profitability

This table compares OptimizeRx and Cardtronics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
Cardtronics1.92%18.43%3.20%

Valuation & Earnings

This table compares OptimizeRx and Cardtronics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
Cardtronics$1.35 billion1.34$48.27 million$2.1618.85

Cardtronics has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than Cardtronics, indicating that it is currently the more affordable of the two stocks.

Summary

Cardtronics beats OptimizeRx on 9 of the 13 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and Repay (NASDAQ:RPAY) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, Repay has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 85.5% of Repay shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 16.5% of Repay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and Repay, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
Repay01902.90

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Repay has a consensus target price of $27.50, indicating a potential upside of 13.78%. Given OptimizeRx's stronger consensus rating and higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than Repay.

Profitability

This table compares OptimizeRx and Repay's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
Repay-32.85%-6.54%-3.77%

Valuation & Earnings

This table compares OptimizeRx and Repay's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
Repay$104.60 million16.97$-40,030,000.00N/AN/A

OptimizeRx has higher earnings, but lower revenue than Repay.

Summary

Repay beats OptimizeRx on 7 of the 12 factors compared between the two stocks.

OptimizeRx (NASDAQ:OPRX) and CBIZ (NYSE:CBZ) are both small-cap computer and technology companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership and analyst recommendations.

Risk & Volatility

OptimizeRx has a beta of 0.56, indicating that its stock price is 44% less volatile than the S&P 500. Comparatively, CBIZ has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.

Insider & Institutional Ownership

58.3% of OptimizeRx shares are owned by institutional investors. Comparatively, 86.4% of CBIZ shares are owned by institutional investors. 8.1% of OptimizeRx shares are owned by company insiders. Comparatively, 7.4% of CBIZ shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings for OptimizeRx and CBIZ, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
OptimizeRx00303.00
CBIZ00103.00

OptimizeRx currently has a consensus target price of $53.3333, indicating a potential upside of 34.88%. Given OptimizeRx's higher possible upside, equities analysts plainly believe OptimizeRx is more favorable than CBIZ.

Profitability

This table compares OptimizeRx and CBIZ's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
OptimizeRx-23.79%-14.44%-11.49%
CBIZ8.08%11.27%5.27%

Valuation & Earnings

This table compares OptimizeRx and CBIZ's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OptimizeRx$24.60 million24.28$-3,140,000.00($0.19)-208.11
CBIZ$948.42 million1.59$70.71 million$1.2721.76

CBIZ has higher revenue and earnings than OptimizeRx. OptimizeRx is trading at a lower price-to-earnings ratio than CBIZ, indicating that it is currently the more affordable of the two stocks.

Summary

CBIZ beats OptimizeRx on 9 of the 13 factors compared between the two stocks.


OptimizeRx Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EVO Payments logo
EVOP
EVO Payments
1.4$27.49-1.0%$2.27 billion$485.78 million-101.81Decrease in Short Interest
TechTarget logo
TTGT
TechTarget
1.5$68.54-0.4%$1.93 billion$133.96 million118.17Decrease in Short Interest
NIC logo
EGOV
NIC
1.6$27.45-0.8%$1.84 billion$354.20 million30.50
Cardtronics logo
CATM
Cardtronics
1.2$40.71-0.2%$1.81 billion$1.35 billion81.42Decrease in Short Interest
RPAY
Repay
1.5$24.17-2.4%$1.77 billion$104.60 million0.00
CBIZ logo
CBZ
CBIZ
1.4$27.64-1.5%$1.51 billion$948.42 million19.88Decrease in Short Interest
Gravity logo
GRVY
Gravity
0.6$190.02-2.4%$1.32 billion$307.18 million32.76Decrease in Short Interest
Radware logo
RDWR
Radware
1.6$27.83-2.9%$1.30 billion$252.07 million77.29
B. Riley Financial logo
RILY
B. Riley Financial
1.1$49.68-0.9%$1.26 billion$652.11 million47.77Insider Buying
Unusual Options Activity
Heavy News Reporting
Tabula Rasa HealthCare logo
TRHC
Tabula Rasa HealthCare
0.9$51.72-7.2%$1.23 billion$284.71 million-25.11Analyst Downgrade
Analyst Revision
Heavy News Reporting
QuinStreet logo
QNST
QuinStreet
1.8$19.70-4.4%$1.04 billion$490.34 million57.94
CNDT
Conduent
1.3$4.81-0.0%$1.01 billion$4.47 billion-1.46
i3 Verticals logo
IIIV
i3 Verticals
1.9$29.58-0.3%$911.72 million$150.13 million-739.50Analyst Report
Heavy News Reporting
GreenSky logo
GSKY
GreenSky
1.7$4.97-1.6%$907.43 million$529.65 million99.42Analyst Revision
IDEX
Ideanomics
0.5$3.18-3.8%$759.93 million$44.57 million-2.69Increase in Short Interest
Heavy News Reporting
Viad logo
VVI
Viad
1.8$37.15-3.3%$758.90 million$1.37 billion-3.91Increase in Short Interest
Collectors Universe logo
CLCT
Collectors Universe
0.6$77.48-0.1%$720.49 million$78.89 million53.81Decrease in Short Interest
Qiwi logo
QIWI
Qiwi
2.3$10.27-3.8%$625.76 million$635.40 million8.49Increase in Short Interest
Liquidity Services logo
LQDT
Liquidity Services
1.1$18.01-3.5%$615.02 million$205.94 million-163.73
Cass Information Systems logo
CASS
Cass Information Systems
1.0$41.59-3.2%$599.81 million$157.24 million24.18
International Money Express logo
IMXI
International Money Express
1.8$15.33-2.2%$583.66 million$319.60 million19.65Heavy News Reporting
MoneyGram International logo
MGI
MoneyGram International
1.2$7.27-3.3%$527.21 million$1.29 billion-19.13
PRTH
Priority Technology
1.1$7.65-0.7%$514.23 million$371.85 million-18.66
RMNI
Rimini Street
1.6$6.50-4.2%$495.85 million$281.05 million-23.21Insider Selling
Decrease in Short Interest
Heavy News Reporting
Limelight Networks logo
LLNW
Limelight Networks
1.9$3.94-5.3%$484.52 million$200.63 million-65.67Heavy News Reporting
Newtek Business Services logo
NEWT
Newtek Business Services
1.6$19.94-1.2%$434.33 million$59.29 million13.38Analyst Downgrade
Heavy News Reporting
DMS
Digital Media Solutions
1.9$11.01-5.8%$356.65 millionN/A0.00
WTRH
Waitr
1.9$3.06-6.2%$339.65 million$191.68 million-0.99Increase in Short Interest
Heavy News Reporting
Emerald logo
EEX
Emerald
1.3$4.53-2.0%$323.63 million$360.90 million-0.50
UXIN
Uxin
0.5$1.05-4.8%$308.23 million$227.64 million-0.61Increase in Short Interest
SCOR
comScore
2.3$3.50-4.3%$254.75 million$388.64 million-4.32Analyst Revision
PAYS
PaySign
1.5$4.73-1.9%$235.76 million$34.67 million43.00
Points International logo
PCOM
Points International
1.1$14.66-4.6%$193.91 million$401.18 million133.28Increase in Short Interest
Heavy News Reporting
PFSweb logo
PFSW
PFSweb
1.4$8.20-1.3%$166.03 million$294.02 million-136.64Analyst Report
Heavy News Reporting
ServiceSource International logo
SREV
ServiceSource International
1.6$1.62-3.1%$156.49 million$216.13 million-8.10
DHI Group logo
DHX
DHI Group
2.1$2.37-1.3%$124.28 million$149.37 million-4.02Decrease in Short Interest
Exela Technologies logo
XELA
Exela Technologies
0.8$0.83-6.0%$122.14 million$1.56 billion-0.24
KRKR
36Kr
1.3$3.19-0.3%$119.61 million$94.17 million-5.70Decrease in Short Interest
Marchex logo
MCHX
Marchex
1.7$2.42-2.1%$95.76 million$106.13 million-3.41
MKD
Molecular Data
0.0$0.80-3.7%$92.60 million$1.90 billion0.00
TC
TuanChe
1.3$3.65-4.9%$71.87 million$92.62 million-9.36Increase in Short Interest
China Customer Relations Centers logo
CCRC
China Customer Relations Centers
0.5$3.85-3.4%$70.57 million$173.41 million0.00Increase in Short Interest
Steel Connect logo
STCN
Steel Connect
0.6$1.09-1.8%$68.45 million$782.81 million-8.38
ALJJ
ALJ Regional
0.6$1.23-11.4%$52.06 million$389.15 million-0.76Increase in Short Interest
Cypress Environmental Partners logo
CELP
Cypress Environmental Partners
1.3$2.80-3.2%$34.19 million$401.65 million-39.99Increase in Short Interest
NCTY
The9
0.5$10.36-15.1%$31.49 million$50,000.000.00Decrease in Short Interest
SGRP
SPAR Group
0.8$1.20-1.7%$25.33 million$252.88 million60.03Decrease in Short Interest
BSQR
BSQUARE
0.5$1.88-4.3%$24.88 million$59.28 million-8.17Increase in Short Interest
Heavy News Reporting
CREG
China Recycling Energy
0.5$6.14-0.7%$19.19 million$870,000.000.00Increase in Short Interest
Heavy News Reporting
SilverSun Technologies logo
SSNT
SilverSun Technologies
0.6$3.37-2.4%$15.17 million$38.50 million0.00Increase in Short Interest
This page was last updated on 1/16/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.